Completed PHASE3 INTERVENTIONAL NCT00099892

Efficacy and Safety of Vildagliptin in Combination With Metformin in Patients With Type 2 Diabetes

Sponsor: Novartis Pharmaceuticals

Updated 5 times since 2017 Last updated: Jul 31, 2017 Started: May 31, 2004 Primary completion: Sep 30, 2005 Completion: Sep 30, 2005

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Diabetes Mellitus, Type 2, this trial is completed. The trial is conducted by Novartis Pharmaceuticals and has accumulated 5 data snapshots since 2004. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

May 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Novartis Pharmaceuticals

Data source: Novartis

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• East Hanover, United States